Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Warning on Interstitial Pneumonia to Be Added to Precautions Section of Package Insert for Rivaroxaban
February 10, 2014
- Bill Payers, Healthcare Providers Agree to Increase Medical Fees, Dispensing Fees
February 7, 2014
- Regulatory Reform Council Selects “Switch-OTC In Vitro Diagnostics” as Target for “International Benchmark Test”
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 1: New Rules Will Spur Efforts to Escape Dependence on Long-Listed Drugs, Spark Reorganization of Generic Industry
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 2: Introduction of New Rule for Long-Listed Drugs, Elimination of Special Price Cuts Could Spark Shift to New Drugs, Use of AG Strategy
February 7, 2014
- Fiscal Impact Assessment for Key Premium Added to Chuikyo’s Supplementary Opinions for FY2014 Revision
February 6, 2014
- Submission of Draft Bills to Establish Japanese Version of US NIH Approved in Joint Session, “NIH” Will Not Be Part of Name
February 6, 2014
- PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
- Revised PAL, Pharmacists Law to Take Effect on June 12
February 5, 2014
- PAFSC’s Second Committee Backs Prostate Cancer Drug Enzalutamide
February 4, 2014
- PMDA Raises Caution about Using Factor Xa Inhibitor Xarelto, Citing Risk of Interstitial Pneumonia
February 4, 2014
- Wholesalers Call on Drug Makers to “Flexibly” Revise Invoice Prices
February 3, 2014
- PAFSC Committee Designates OTC PMS Treatment as First “Drug Requiring Guidance”
January 31, 2014
- Medical Fee Cuts Will Start from FY2014 to Improve Delivery Price Settlement Rates: Chuikyo
January 30, 2014
- Wary of Drug Price Negotiations Dragging Out into FY2014, MHLW to Survey Price Agreement Rate in March
January 30, 2014
- 2 Bills Related to the Establishment of a “Japanese NIH” to Be Submitted to the Diet in Early February
January 30, 2014
- 3 Entities Strike Codevelopment Deal for Adult TB Vaccines
January 29, 2014
- Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA
January 29, 2014
- PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3
January 28, 2014
- MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…